Europe Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Product Type (Instruments, Assay Kits & Consumables), By Disease Type (Systemic Autoimmune Diseases), By Technology (Immunoassays, Indirect Immunofluorescence, Multiplex Assays, Molecular Diagnostics, Point-of-Care Testing, Other Technology), By End User (Hospitals & Clinics, Clinical Laboratories, Academic & Research Institutes, Other End Users) and By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, Rest of Europ) Forecasts, 2026-2034

Market Overview

The europe autoimmune disease diagnostics market size was valued at USD 1.93 billion in 2025 and is projected to grow from USD 2.08 billion in 2026 to reach USD 3.83 billion in 2034, growing at a CAGR of 7.9% during the forecast period 2026–2034.

Autoimmune illnesses are also characterized by the activation of self-reactive T cells, the production of autoantibodies, and inflammation. Immune cells may recognize foreign substances such as bacteria and viruses and send out fighter cells to combat them. The immune system is forced to combat itself in autoimmune illnesses.

But in certain cases, the immune system misidentifies parts of your body, such as your joints or skin, as an alien in an autoimmune disease. Autoantibodies are proteins released by the body that assault healthy cells. Some autoimmune disorders are limited to a single organ. The pancreas is harmed by type 1 diabetes. Systemic lupus erythematosus (SLE), for example, affects the entire body. These are non-communicable conditions in which the immune system loses its natural balance. This organism is in charge of causing an abnormal response in its tissue cells.

Europe Autoimmune Disease Diagnostics Market Segmentation Analysis

By Product Type

The Europe Autoimmune Disease Diagnostics Market is segmented into Instruments and Assay Kits & Consumables. Instruments include automated analyzers, immunoassay systems, fluorescence-based diagnostic platforms, and other laboratory equipment used to detect and characterize autoimmune biomarkers, while assay kits and consumables include reagents, test kits, antibodies, calibrators, controls, and other materials required for diagnostic testing. Instruments support automation, standardization, and high-throughput testing in clinical laboratories, whereas assay kits and consumables are required for routine and specialized autoimmune disease testing. Increasing demand for accurate diagnosis and laboratory automation is supporting adoption across both product categories.

Growing awareness of autoimmune disorders, increasing diagnostic testing volumes, technological advancements, and the expansion of clinical laboratory infrastructure are supporting market growth across Europe. Instruments are benefiting from demand for automated and integrated diagnostic platforms that improve workflow efficiency and testing consistency, while assay kits and consumables benefit from recurring demand associated with routine laboratory testing. The increasing focus on early disease detection, personalized treatment strategies, and improved diagnostic accuracy is expected to create continued opportunities for manufacturers of autoimmune diagnostic instruments and consumables.

Request Customizationto receive a tailored report.

By Disease Type

The Europe Autoimmune Disease Diagnostics Market is segmented by disease type, with Systemic Autoimmune Diseases representing a key category. Systemic autoimmune diseases occur when immune system dysfunction affects multiple organs or tissues and include conditions such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjögren's syndrome, and other systemic autoimmune disorders. Diagnosis often requires a combination of clinical assessment and laboratory testing for autoantibodies and other biomarkers. Increasing demand for reliable laboratory confirmation is supporting the use of specialized autoimmune diagnostic tests for systemic conditions.

The increasing prevalence and clinical burden of systemic autoimmune diseases, particularly among aging populations and individuals with complex chronic conditions, are driving demand for diagnostic testing across Europe. Early and accurate diagnosis can support appropriate treatment selection and disease monitoring, encouraging healthcare providers to adopt sensitive and specific diagnostic technologies. Continued development of biomarker-based testing, improved laboratory automation, and growing awareness among healthcare professionals are expected to support further expansion of systemic autoimmune disease diagnostics.

By Technology

The Europe Autoimmune Disease Diagnostics Market is segmented into Immunoassays, Indirect Immunofluorescence, Multiplex Assays, Molecular Diagnostics, Point-of-Care Testing, and Other Technology. Immunoassays are widely used to detect autoantibodies and other disease-related biomarkers, while indirect immunofluorescence is commonly used for antibody screening and pattern identification. Multiplex assays enable simultaneous analysis of multiple biomarkers, molecular diagnostics provide nucleic-acid-based testing capabilities for selected applications, and point-of-care testing allows diagnostic assessment closer to the patient. Other technologies include emerging and specialized diagnostic approaches used for autoimmune disease detection and monitoring.

Increasing demand for faster, accurate, and more comprehensive autoimmune testing is supporting technological advancement across Europe. Immunoassays continue to benefit from broad clinical adoption and automation, while multiplex assays are gaining importance because they can evaluate multiple biomarkers in a single testing workflow. Molecular diagnostics and point-of-care technologies are also creating opportunities by supporting more specialized and accessible testing. Growing investments in laboratory automation, precision medicine, biomarker discovery, and advanced diagnostic platforms are expected to strengthen adoption of innovative technologies in autoimmune disease diagnostics.

By End User

The Europe Autoimmune Disease Diagnostics Market is segmented into Hospitals & Clinics, Clinical Laboratories, Academic & Research Institutes, and Other End Users. Hospitals and clinics use autoimmune diagnostic tests for patient evaluation, disease confirmation, treatment planning, and monitoring, while clinical laboratories perform high volumes of specialized testing and provide diagnostic services to healthcare facilities. Academic and research institutes use autoimmune diagnostic technologies for biomarker discovery, disease research, clinical studies, and development of new diagnostic approaches. Other end users include specialized healthcare and research organizations requiring autoimmune testing capabilities.

Clinical laboratories represent an important end-user category because of their role in centralized and specialized autoimmune testing, while hospitals and clinics continue to generate demand through increasing patient diagnosis and monitoring requirements. Academic and research institutes are also contributing to technological development through research into disease mechanisms, biomarkers, and personalized treatment approaches. Increasing healthcare expenditure, expansion of laboratory infrastructure, rising diagnostic awareness, and growing demand for early and accurate autoimmune disease detection are expected to support adoption across hospitals and clinics, clinical laboratories, research institutes, and other end-user settings.

Speak to an Analystto discuss market opportunities.

Regional Analysis

List of Key and Emerging Players in Europe Autoimmune Disease Diagnostics Market